Treprostinil diolamine
Orenitram, Remodulin, Treprostinil, Trepulmix, Tyvaso (treprostinil diolamine) is a small molecule pharmaceutical. Treprostinil diolamine was first approved as Remodulin on 2002-05-21. It is used to treat pulmonary hypertension in the USA. It has been approved in Europe to treat pulmonary hypertension.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| respiratory tract diseases | D012140 |
| cardiovascular diseases | D002318 |
Trade Name
FDA
EMA
Orenitram
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Treprostinil diolamine
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| ORENITRAM | United Therapeutics | N-203496 RX | 2013-12-20 | 5 products, RLD |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| diluent treprostinil | ANDA | 2023-04-06 |
| orenitram | New Drug Application | 2024-11-20 |
| remodulin | New Drug Application | 2014-12-31 |
| remodulin sterile diluent for remodulin | New Drug Application | 2024-12-10 |
| sterile diluent for treprostinil treprostinil | ANDA | 2021-12-23 |
| treprostinil | ANDA | 2025-01-10 |
| tyvaso | New Drug Application | 2024-12-13 |
| tyvaso dpi | New Drug Application | 2024-12-13 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| pulmonary hypertension | EFO_0001361 | D006976 | I27.20 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
TREPROSTINIL DIOLAMINE, ORENITRAM, UNITED THERAP | |||
| 2026-10-18 | ODE-272 | ||
TREPROSTINIL, TYVASO, UNITED THERAP | |||
| 2024-03-31 | I-856 | ||
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Treprostinil, Tyvaso, United Therap | |||
| 11826327 | 2042-01-04 | U-3749 | |
| 9358240 | 2028-05-05 | U-1849 | |
| 9339507 | 2028-03-10 | DP | |
| 10376525 | 2027-05-14 | U-1849 | |
| 10716793 | 2027-05-14 | U-1849 | |
| Treprostinil, Tyvaso Dpi, United Therap | |||
| 10421729 | 2035-04-01 | DP | |
| 10772883 | 2030-06-11 | DP | |
| 10130685 | 2025-08-23 | DP | |
| Treprostinil Diolamine, Orenitram, United Therap | |||
| 8747897 | 2031-08-11 | DP | U-2724, U-2725 |
| 8349892 | 2031-01-22 | DP | |
| 8410169 | 2030-02-13 | DP | |
| 8497393 | 2028-12-15 | DP | |
| 7417070 | 2026-07-30 | DP | |
| 9393203 | 2026-04-27 | DP | U-1877 |
| 7544713 | 2024-07-14 | U-1475 | |
| 8252839 | 2024-05-24 | DP | |
| 9050311 | 2024-05-24 | DS, DP | |
| 9278901 | 2024-05-24 | U-1475 | |
| 9422223 | 2024-05-24 | DP | |
| Treprostinil, Remodulin, United Therap | |||
| 7999007 | 2029-03-29 | DP | U-1437 |
| 9593066 | 2028-12-15 | DP | |
| 9604901 | 2028-12-15 | DP | |
| 11723887 | 2028-12-15 | DP | |
| 8653137 | 2028-09-05 | U-1437 | |
| 8658694 | 2028-09-05 | U-1437 | |
| 9713599 | 2024-12-16 | U-2036 | |
| 10076505 | 2024-12-16 | DP | |
| 10695308 | 2024-12-16 | U-2845 | |
| 9199908 | 2024-05-24 | U-1771 | |
HCPCS
No data
Clinical
Clinical Trials
137 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hypertension | D006973 | EFO_0000537 | I10 | 4 | 14 | 19 | 15 | 11 | 61 |
| Pulmonary arterial hypertension | D000081029 | — | — | 7 | 7 | 12 | 13 | 11 | 50 |
| Familial primary pulmonary hypertension | D065627 | — | I27.0 | 1 | 4 | 7 | 11 | 7 | 30 |
| Pulmonary hypertension | D006976 | EFO_0001361 | I27.20 | 2 | 10 | 13 | 4 | 3 | 30 |
| Ventricular remodeling | D020257 | — | — | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Lung diseases | D008171 | EFO_0003818 | J98.4 | — | 6 | 8 | — | 2 | 14 |
| Interstitial lung diseases | D017563 | EFO_0004244 | J84.9 | — | 5 | 6 | — | 1 | 10 |
| Pulmonary fibrosis | D011658 | — | J84.10 | — | 4 | 6 | — | — | 8 |
| Fibrosis | D005355 | — | — | — | 2 | 4 | — | — | 6 |
| Chronic obstructive pulmonary disease | D029424 | EFO_0000341 | J44.9 | — | 1 | 2 | — | 1 | 4 |
| Obstructive lung diseases | D008173 | — | — | — | 1 | 2 | — | 1 | 4 |
| Idiopathic pulmonary fibrosis | D054990 | — | J84.112 | — | 1 | 3 | — | — | 4 |
| Ischemia | D007511 | EFO_0000556 | — | 1 | 3 | 2 | — | — | 4 |
| Chronic limb-threatening ischemia | D000089802 | — | — | — | 2 | 2 | — | — | 3 |
| Emphysema | D004646 | EFO_0000464 | J43 | — | 2 | 2 | — | — | 2 |
Show 7 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Systemic scleroderma | D012595 | EFO_0000717 | M34 | 1 | 3 | — | — | — | 4 |
| Diffuse scleroderma | D045743 | EFO_0000404 | — | 1 | 3 | — | — | — | 4 |
| Sclerosis | D012598 | — | — | 1 | 2 | — | — | — | 3 |
| Persistent fetal circulation syndrome | D010547 | EFO_1001103 | P29.3 | — | 1 | — | — | — | 1 |
| Localized scleroderma | D012594 | EFO_1001361 | L94.0 | — | 1 | — | — | — | 1 |
| Sarcoidosis | D012507 | EFO_0000690 | D80-D89 | — | 1 | — | — | — | 1 |
| Wounds and injuries | D014947 | — | T14.8 | 1 | 1 | — | — | — | 1 |
| Reperfusion injury | D015427 | — | — | 1 | 1 | — | — | — | 1 |
| Delayed graft function | D051799 | — | — | 1 | 1 | — | — | — | 1 |
| Pain | D010146 | EFO_0003843 | R52 | — | 1 | — | — | — | 1 |
Show 4 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 2 | — | — | — | — | 2 |
| Renal insufficiency | D051437 | — | N19 | 1 | — | — | — | — | 1 |
| Raynaud disease | D011928 | EFO_1001145 | I73.0 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Congenital heart defects | D006330 | — | Q24.9 | — | — | — | — | 1 | 1 |
| Heart diseases | D006331 | EFO_0003777 | I51.9 | — | — | — | — | 1 | 1 |
| Hypoxia | D000860 | — | R09.02 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Treprostinil diolamine |
| INN | treprostinil |
| Description | Orenitram, Remodulin, Trepulmix, Tyvaso (treprostinil diolamine) is a small molecule pharmaceutical. Treprostinil diolamine was first approved as Remodulin on 2002-05-21. It is used to treat pulmonary hypertension in the USA. It has been approved in Europe to treat pulmonary hypertension. |
| Classification | Small molecule |
| Drug class | prostaglandins |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CCCCC[C@H](O)CC[C@@H]1[C@H]2Cc3cccc(OCC(=O)O)c3C[C@H]2C[C@H]1O.OCCNCCO |
Identifiers
| PDB | — |
| CAS-ID | 830354-48-8 |
| RxCUI | — |
| ChEMBL ID | CHEMBL2107815 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | RUM6K67ESG (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Remodulin – United Therapeutics
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tyvaso – United Therapeutics
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Orenitram – United Therapeutics
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 2,638 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
89,620 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use